文献速递淋巴瘤

整合弥漫性大B细胞淋巴瘤基因组改变识别新的相关通路和潜在治疗靶点

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
PubMed 文献 · Leukemia · 2017-08-14

该研究对150例弥漫性大B细胞淋巴瘤(DLBCL)进行106个基因的靶向二代测序和基因组拷贝数改变(CNA)整合分析,并在111例独立队列中验证。生发中心B细胞和活化B细胞DLBCL具有不同的突变谱、致病通路和CNA。NOTCH通路基因和抑癌基因(TP53/CDKN2A)突变(而非单个基因)赋予不良预后,并在验证队列中确认。

要点

  • NOTCH通路基因和抑癌基因(TP53/CDKN2A)突变(非单个基因)与不良预后相关
  • 生发中心B细胞和活化B细胞DLBCL具有不同的突变谱、致病通路和CNA
  • 69例(46%)携带至少一个基因组改变,被识别为潜在药物反应靶点

核心结论

  • 本研究识别了DLBCL中的相关通路和突变基因,并确定了新干预策略的潜在靶点。

研究设计与样本

  • 对150例DLBCL进行106个基因的靶向二代测序和基因组拷贝数改变(CNA)整合分析,临床显著发现在一个111例患者的独立队列中验证。

主要发现

  • 生发中心B细胞和活化B细胞DLBCL具有不同的突变谱、 altered致病通路和CNA。
  • NOTCH通路基因和抑癌基因(TP53/CDKN2A)突变(而非单个基因)赋予不良预后,并在独立验证队列中确认。
  • 基因表达谱分析显示,携带NOTCH通路突变的肿瘤下游靶基因有显著调节,强调该通路在DLBCL中的相关性。
  • 计算机药物发现分析识别出69例(46%)携带至少一个基因组改变,根据早期临床试验或临床前试验在DLBCL或其他淋巴瘤中被视为药物反应的潜在靶点。

关键数值与推荐

  • NOTCH通路基因和抑癌基因(TP53/CDKN2A)突变(而非单个基因)赋予不良预后。
  • 计算机药物发现分析识别出69例(46%)携带至少一个基因组改变,被视为药物反应的潜在靶点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Karube K, Enjuanes A, Dlouhy I, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2017. PMID: 28804123. doi:10.1038/leu.2017.251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。